Strength of patient cohorts and biobanks for cardiomyopathy research

DOSIS consortium

doi:https://doi.org/10.1007/s12471-020-01456-4

Strength of patient cohorts and biobanks for cardiomyopathy research

DOSIS consortium

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

Original language	English
Pages (from-to)	50-56
Number of pages	7
Journal	Netherlands heart journal
Volume	28
DOIs	https://doi.org/10.1007/s12471-020-01456-4
Publication status	Published - 1 Aug 2020

Keywords

Cardiomyopathies
Gene variants
Patient cohorts

Access to Document

https://doi.org/10.1007/s12471-020-01456-4

Cite this

@article{b4eb5d7ee6dd40ef9c19773d2b6f3212,

title = "Strength of patient cohorts and biobanks for cardiomyopathy research",

abstract = "In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.",

keywords = "Cardiomyopathies, Gene variants, Patient cohorts",

author = "{DOSIS consortium} and {de Boer}, {R. A.} and Nijenkamp, {L. L.A.M.} and Sillj{\'e}, {H. H.W.} and Eijgenraam, {T. R.} and R. Parbhudayal and {van Driel}, B. and R. Huurman and M. Michels and J. Pei and M. Harakalova and {van Lint}, {F. H.M.} and M. Jansen and Baas, {A. F.} and Asselbergs, {F. W.} and {van Tintelen}, {J. P.} and Brundel, {B. J.J.M.} and Dorsch, {L. M.} and M. Schuldt and Kuster, {D. W.D.} and {van der Velden}, J.",

year = "2020",

month = aug,

day = "1",

doi = "https://doi.org/10.1007/s12471-020-01456-4",

language = "English",

volume = "28",

pages = "50--56",

journal = "Netherlands heart journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

}

TY - JOUR

T1 - Strength of patient cohorts and biobanks for cardiomyopathy research

AU - DOSIS consortium

AU - de Boer, R. A.

AU - Nijenkamp, L. L.A.M.

AU - Silljé, H. H.W.

AU - Eijgenraam, T. R.

AU - Parbhudayal, R.

AU - van Driel, B.

AU - Huurman, R.

AU - Michels, M.

AU - Pei, J.

AU - Harakalova, M.

AU - van Lint, F. H.M.

AU - Jansen, M.

AU - Baas, A. F.

AU - Asselbergs, F. W.

AU - van Tintelen, J. P.

AU - Brundel, B. J.J.M.

AU - Dorsch, L. M.

AU - Schuldt, M.

AU - Kuster, D. W.D.

AU - van der Velden, J.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

AB - In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

KW - Cardiomyopathies

KW - Gene variants

KW - Patient cohorts

UR - http://www.scopus.com/inward/record.url?scp=85089266827&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s12471-020-01456-4

DO - https://doi.org/10.1007/s12471-020-01456-4

M3 - Review article

C2 - 32780332

SN - 1568-5888

VL - 28

SP - 50

EP - 56

JO - Netherlands heart journal

JF - Netherlands heart journal

ER -

Strength of patient cohorts and biobanks for cardiomyopathy research

Abstract

Keywords

Access to Document

Other files and links

Cite this